Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$161.01 - $317.85 $1.54 Million - $3.05 Million
9,591 Added 1.9%
515,024 $163 Million
Q3 2023

Nov 14, 2023

BUY
$164.66 - $218.08 $1.96 Million - $2.6 Million
11,906 Added 2.41%
505,433 $85.5 Million
Q1 2023

May 15, 2023

BUY
$161.33 - $204.36 $12.9 Million - $16.3 Million
79,765 Added 19.28%
493,527 $89.6 Million
Q3 2022

Nov 14, 2022

SELL
$123.79 - $277.42 $3.48 Million - $7.8 Million
-28,131 Reduced 6.37%
413,762 $93.1 Million
Q2 2022

Aug 15, 2022

BUY
$93.97 - $143.33 $878,619 - $1.34 Million
9,350 Added 2.16%
441,893 $55.9 Million
Q1 2022

May 16, 2022

BUY
$98.9 - $132.37 $563,730 - $754,509
5,700 Added 1.34%
432,543 $54.8 Million
Q4 2021

Feb 14, 2022

BUY
$110.64 - $159.4 $3.86 Million - $5.57 Million
34,926 Added 8.91%
426,843 $55.9 Million
Q3 2021

Nov 15, 2021

BUY
$101.2 - $125.87 $536,258 - $666,985
5,299 Added 1.37%
391,917 $47.9 Million
Q2 2021

Aug 16, 2021

BUY
$107.45 - $135.95 $1.92 Million - $2.43 Million
17,854 Added 4.84%
386,618 $44.1 Million
Q1 2021

May 17, 2021

BUY
$95.46 - $133.08 $11.9 Million - $16.6 Million
124,814 Added 51.16%
368,764 $44.3 Million
Q4 2020

Feb 16, 2021

SELL
$75.23 - $109.23 $11,735 - $17,039
-156 Reduced 0.06%
243,950 $24.8 Million
Q3 2020

Nov 16, 2020

BUY
$71.31 - $109.74 $2.91 Million - $4.48 Million
40,794 Added 20.06%
244,106 $18.9 Million
Q2 2020

Aug 14, 2020

BUY
$62.14 - $117.21 $1.45 Million - $2.73 Million
23,312 Added 12.95%
203,312 $22.7 Million
Q4 2019

Feb 14, 2020

SELL
$11.44 - $123.99 $2.06 Million - $22.4 Million
-180,400 Reduced 50.06%
180,000 $13.6 Million
Q3 2019

Nov 14, 2019

SELL
$16.05 - $27.35 $852,255 - $1.45 Million
-53,100 Reduced 12.84%
360,400 $5.88 Million
Q2 2019

Aug 14, 2019

BUY
$20.02 - $20.02 $8.28 Million - $8.28 Million
413,500 New
413,500 $8.28 Million

Others Institutions Holding KRTX

About Karuna Therapeutics, Inc.


  • Ticker KRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,965,000
  • Description
  • Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...
More about KRTX
Track This Portfolio

Track Rock Springs Capital Management LP Portfolio

Follow Rock Springs Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rock Springs Capital Management LP with notifications on news.